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Original Article
Quantitative parametric maps of
O-(2-[18F]fluoroethyl)-L-tyrosine
kinetics in diffuse glioma
Thomas Koopman1 , Niels Verburg2,3, Petra JW Pouwels1,
Pieter Wesseling4,5,6, Otto S Hoekstra1,
Philip C De Witt Hamer2,3, Adriaan A Lammertsma1 ,
Maqsood Yaqub1 and Ronald Boellaard1,7
Abstract
Quantitative parametric images of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in diffuse gliomas could be used to improve
glioma grading, tumour delineation or the assessment of the uptake distribution of this positron emission tomography
tracer. In this study, several parametric images and tumour-to-normal maps were compared in terms of accuracy of
region averages (when compared to results from nonlinear regression of a reversible two-tissue compartment plasma
input model) and image noise using 90 min of dynamic scan data acquired in seven patients with diffuse glioma. We
included plasma input methods (the basis function implementation of the single-tissue compartment model, spectral
analysis and Logan graphical analysis) and reference tissue methods (basis function implementations of the simplified
reference tissue model, variations of the multilinear reference tissue model and non-invasive Logan graphical analysis) as
well as tumour-to-normal ratio maps at three intervals. (Non-invasive) Logan graphical analysis provided volume of
distribution maps and distribution volume ratio maps with the lowest level of noise, while the basis function implemen-
tations provided the best accuracy. Tumour-to-normal ratio maps provided better results if later interval times
were used, i.e. 60–90 min instead of 20–40 min, leading to lower bias (2.9% vs. 10.8%, respectively) and less noise
(12.8% vs. 14.4%).
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Introduction
Diffuse gliomas exhibit increased uptake and retention
of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET), an
amino acid tracer that can be visualised with positron
emission tomography (PET). In a previous study, the
optimal plasma input model for describing [18F]FET
kinetics was identified.1 However, VOIs have to be
defined beforehand and tracer uptake distributions
cannot be assessed. The currently recommended2
[18F]FET PET standardized uptake value (SUV)
image at 20–40min shows good contrast between
lesions and healthy tissue. Interpatient differences are
reduced by normalizing tumour uptake to that in a
contralateral healthy region. Indeed, a tumour-to-
normal ratio at 20–40min is widely used for tumour
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delineation.3 At the same time, many other studies have
used a dynamic scanning protocol, mostly for discrimi-
nating different tumour types based on uptake pat-
terns.3 Several methods exist for ‘‘catching’’ tracer
kinetics into parametric images. In theory, parametric
images are more accurate than SUV images or tumour-
to-normal maps, and may be better for glioma grading
or delineation. Yet Logan graphical analysis has been
the only parametric method for quantifying [18F]FET
uptake so far.4–6
The aim of this study was to determine the accuracy
of parametric images and tumour-to-normal maps for
quantifying [18F]FET uptake. Results obtained using
the previously identified plasma input model were
used as reference. In addition, image noise characteris-
tics of the maps were taken into account.
Methods
Subjects
Data were derived from a study that has been reported
previously.1,7 In short, the study population consisted
of seven patients with a diffuse glioma (age range, 22–
69 y; four glioma WHO8 grade IV and three grade II).
This study has been performed in accordance with the
Declaration of Helsinki, approved by the Medical
Ethics Committee of the VU University Medical
Center and registered in the Netherlands National
Trial Register (www.trialregister.nl, unique identifier
NTR5354, registration date 4 August 2015). Written,
informed consent was obtained from all subjects prior
to inclusion.
Scanning protocol
Magnetic resonance (MR) sequences were acquired on
an Achieva whole body 3.0T MR scanner (Philips
Healthcare, Best, the Netherlands), equipped with a
standard head coil. Each patient was scanned using a
sagittal 3D fluid-attenuated inversion recovery
(FLAIR) sequence (repetition time(TR)/echo
time(TE)/inversion time(TI) 4800/279/1650ms,
acquired voxel size 1.12 1.12 1.12mm3, recon-
structed voxel size 1.04 1.04 0.56mm3), and a sagit-
tal 3D T1-weighted gadolinium-enhanced (T1G)
sequence (TR/TE/TI/flip angle 7/3/950ms/12 ,
acquired voxel size 0.98 0.98 1.0mm3, recon-
structed voxel size 0.87 0.87 1.0mm3). A dynamic
PET scan was acquired on either a Gemini TF-64 or
an Ingenuity TF PET/computed tomography (CT)
scanner (Philips Healthcare, Cleveland, Ohio, USA).
Each scan started with a 1min low dose CT scan for
attenuation correction purposes. Next, a 90min PET
scan was acquired after administration of 200MBq
[18F]FET. The tracer was injected using a venous line,
while an arterial line in the opposite arm was used for
continuous sampling using an on-line blood sampler
(Comecer Netherlands, Joure, the Netherlands). In
addition, manual arterial samples were collected at 5,
10, 20, 40, 60, 75 and 90min post injection of [18F]FET.
Using the LOR-RAMLA algorithm, as provided by the
manufacturer, scans were reconstructed into 22 frames
(1 15, 3 5, 3 10, 4 60, 2 150, 2 300,
7 600 s), with an isotropic voxel size of 2mm.
Reconstructions included all usual corrections, i.e. nor-
malization, decay, dead time, attenuation, randoms and
scatter correction. The manual blood samples were
used to calibrate the on-line blood curve and to correct
it for plasma-to-whole blood concentration ratios and
labelled metabolite fractions, thereby generating a
metabolite corrected, arterial plasma input function.
Data analysis
Glioblastomas were delineated on T1-weighted gadoli-
nium-enhanced MRI images (T1G) and lower grade
gliomas on FLAIR MRI images. As described else-
where,1 tumour segmentations were divided into three
equal sized volumes of interest (VOI) using the 33rd
and 67th percentiles of the activity concentrations of
[18F]FET at 20 to 40min. A spherical reference region
with a radius of 14mm was placed in the middle of the
contralateral homologous brain region.1 Time activity
curves were extracted from these regions, which were
fitted to the reversible two-tissue compartment plasma
input model with additional blood volume fraction
using nonlinear regression. In earlier work,1 we found
that reversible models were always preferred over the
irreversible model in both tumour and reference regions
and that the reversible two-tissue compartment model
was preferred over the reversible single-tissue compart-
ment model in most cases. The total volume of distri-
bution (VT) was used as outcome measure. The
distribution volume ratio (DVR) was calculated by nor-
malizing the VT to the VT of the reference region.
Results for both parameters served as reference stand-
ard for the agreement analysis.
Parametric VT images were created using a basis
function implementation of the reversible single-tissue
compartment model (BFM),9 plasma input-based
Logan graphical analysis (Logan)10 and spectral ana-
lysis (SA).11 Using the contralateral reference region,
reference input-based Logan analysis (RLogan)12 was
used to create a DVR map. Non-displaceable binding
potential (BPND) maps were generated with basis func-
tion implementations of the simplified reference tissue
model (receptor parametric mapping (RPM) and
SRTM2)
13,14 and using several variations of the multi-
linear reference tissue model (MRTMO, MRTM,
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MRTM2, MRTM3 and MRTM4).
15–17 MRTM2,
MRTM3, MRTM4 and SRTM2 are all methods using
a fixed k
0
2 (the clearance rate of the reference tissue)
based on the median value from a first run. They are
based on MRTM, MRTMO, MRTMO and RPM,
respectively. MRTM4 uses a different model in the
first run where the fixed k
0
2 is based on MRTM. The
BPND maps were converted to DVR maps using
DVR¼BPNDþ 1. Each method was applied using
only the first 60min of the acquired data to investigate
the possibility of shortening scanning times, indicated
in the results by 60 in superscript. Finally, standardized
uptake value ratio (SUVr, also known as tumour-to-
normal ratio) maps were created for three intervals:
20–40, 40–60 and 60–90min with intervals indicated
by superscripts. SUVr was calculated by normalizing
to the average uptake value in the reference region.
All maps were visually inspected for artefacts. After
extracting average regional values from the parametric
images, Bland–Altman analysis18 was used to deter-
mine the accuracy, i.e. the agreement with the reference,
described above. Relative differences were calculated by
dividing the difference by the reference. Results were
summarized by both mean and standard deviation of
these relative differences.
The 3D T1G sequence was used for segmenting grey
matter with SPM12.19 The grey matter probability map
of the whole brain, including cerebellum, was converted
to a binary mask using an intensity cut-off of 0.9. The
tumour VOI was excluded from the grey matter mask
to obtain a mask with only normal appearing brain
tissue. This region was used to estimate image noise
in the parametric maps by means of the coefficient of
variation (COV, the standard deviation divided by the
mean) of the voxel values within the region. These
image noise estimates were used to rank the methods
with respect to image quality.
Logan, RLogan and MRTM variations are lineariza-
tion methods and require a start time (t*) representing
the time beyond which the linear fit can be applied. The
other methods are basis function implementations and
require a range and number of basis functions. Settings
were optimized for each method in preliminary analysis,
selecting the settings producing the best accuracy. The
settings used for each method are listed in Table 1.
Results
Typical parametric maps of all methods are shown in
Figure 1, using the three intervals for the SUVr images
and 90min of data for the other methods. Upon visual
inspection, it became evident the BFM maps contained
an artefact: boundaries appeared due to sudden steps in
VT values, forming patches throughout the brain. We will
refer to this as patchiness. The RPM maps showed a
similar effect and the SRTM2 maps showed some patchi-
ness mostly in white matter. These patches can sometimes
be situated near or inside the tumour region. MRTM
maps suffered from ‘dot artefacts’—isolated voxels show-
ing very high or very low values—resulting in high esti-
mated image noise. The SUVr maps showed a decreasing
contrast between tumour and normal brain for later
intervals for most glioblastoma patients. The glioblast-
oma patient where this effect was strongest is shown in
Figure 1. All results are summarized in Table 2.
The results on accuracy for VT are shown in
Figure 2(a), which shows the relative agreement with
the reference standard. The highest accuracy when
using 90min of data was observed for BFM with a
standard deviation of 5.7% and a small average under-
estimation of 4.9%. Logan shows a larger standard
deviation, 7.5%, and a larger and consistent underesti-
mation, 12%. SA had the lowest accuracy with a
standard deviation of 9.4% and an average overesti-
mation of 19%. The measured image noise, i.e. COV
of every VT map is visualized in Figure 2(b). In terms of
image noise, BFM was found to be the worst of the
three, with an average COV of 15.9%. This is in line
with visual inspection, as described above. Logan
showed the lowest level of image noise with an average
COV of 13.2%. SA showed an average COV of 14.2%.
When using 60min of data, the accuracy became worse
for all methods, but their ranking remained the same,
and the average image noise COV rises to more than
16% for all methods.
Results on accuracy and the measured COVs for
DVR maps are shown in Figure 3. Using 90min of
data, RLogan provided the best maps in terms of
image noise with a COV of 12.1%. In terms of agree-
ment with results from the reference standard, however,
it showed a wide range of differences with a standard
deviation of 18.3% and an average overestimation of
7.3%. RPM provided the best accuracy with a standard
deviation of 7.8% and a mean overestimation of 0.9%,
but showed poor performance in terms of image noise.
Observed image noise was less for SRTM2 maps.
However, the accuracy of SRTM2 maps was poorer
with a standard deviation of 12.0% and an average
overestimation of 6.7%.
When using 90min of data, MRTMO showed little
noise, yet the standard deviation of the differences was
higher than for RPM, SRTM2, MRTM and SUVr
60–90.
MRTM3, where the k
0
2 in MRTMO is fixed, was com-
parable to MRTMO in terms of noise, but poorer in
accuracy. MRTM performed better than MRTMO
in terms of accuracy, but showed poor performance
in terms of noise, agreeing with visual inspection
described above. Both MRTM2 and MRTM4 showed
inconsistent results: for most patients the maps showed
large offsets, negative or positive, resulting in high









































Figure 1. Typical parametric and SUVr (tumour-to-normal) maps. Left is a patient with an oligodendrocytoma, right is a glioblastoma
patient.
Table 1. Parametric methods and settings.
Method Parameter Start time (min) Basis function range (min-1)
Number of
basis functions
BFM VT 0.01–0.5 50
SA VT 0.01–4 50
Logan VT 10
RLogan DVR 30
RPM BPNDþ1¼DVR 0.01–4 50
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standard deviations of differences (36.3% to 440%).
Note that MRTM2 and MRTM4 were not included in
Figure 3(a) to more clearly show the differences
between the other methods. For the same reason,
RPM60, MRTM60O , MRTM, MRTM2, MRTM
60
3 and
MRTM4 were not included in Figure 3(b). These data
can be found in the supplemental material.
Amongst the SUVr maps, the 60–90min interval was
the best in terms of accuracy as well as image noise.
SUVr60–90 showed accuracy comparable with MRTM
and SRTM2 and in terms of image noise it was com-
parable to SRTM2, although SRTM2 shows some
abnormal patches mostly in white matter, which was
not included in noise estimation.
Discussion
An important finding of this study is that, in general,
less noise in the images (COV of voxel values) is asso-






SD (%) Mean (%) COV (%) Mean SD
BFM
90 5.7 4.9 15.9 1.48 0.45
60 7.9 9.2 21.1 1.47 0.46
Logan
90 7.5 12.1 13.2 1.51 0.46
60 10.3 20.7 16.2 1.52 0.50
SA
90 9.4 19.4 14.2 1.45 0.43
60 12.3 24.8 16.1 1.45 0.45
RLogan
90 18.3 7.3 12.1 1.54 0.46
60 21.8 9.3 13.7 1.57 0.50
RPM
90 7.8 0.9 20.8 1.46 0.40
60 8.2 0.5 26.5 1.44 0.44
SRTM2
90 12.0 6.7 12.7 1.54 0.44
60 15.2 9.3 14.4 1.58 0.47
MRTMO
90 15.6 4.4 12.4 1.50 0.45
60 19.0 6.0 54.2 1.53 0.48
MRTM
90 11.6 4.3 85.7 1.51 0.46
60 19.0 6.4 74.6 1.53 0.49
MRTM2
90 139.9 67.5 229.8 2.37 1.85
60 44.0 2.8 146.5 1.44 0.89
MRTM3
90 16.0 4.8 12.3 1.51 0.44
60 21.1 3.5 25.7 1.49 0.48
MRTM4
90 36.2 3.1 24.1 1.46 0.54
60 440.7 433.6 34.4 6.76 5.70
SUVr
60–90 12.4 2.9 12.8 1.48 0.43
40–60 17.9 6.0 13.5 1.53 0.47
20–40 27.1 10.8 14.4 1.59 0.54
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words, the optimal parametric method depends on the
specific application where it is used for. Some methods,
however, showed better performance than others and
can be recommended for further research. For estima-
tion of VT, BFM showed the best accuracy, while in
terms of noise, Logan plots show the best performance.
For estimation of DVR, MRTMO, MRTM3 and
RLogan plots showed good results in terms of image
noise, but performed relatively poor in terms of accur-
acy, i.e. these methods showed some larger variance in
differences with the reference. RPM showed the best
accuracy, followed by MRTM, but both methods
showed relatively high image noise levels. SRTM2 and
SUVr60–90 showed comparable results both in terms of
estimated image noise and accuracy.
Patchiness in BFM VT maps can be seen especially in
areas with low tracer uptake. The rate constants are
difficult to determine in these areas because k2 reaches
the lower limit. Although lowering the limit results in
fewer and smaller patches, it also results in more prom-
inent patches because contrast with surrounding tissue
becomes higher. Because some of the patches are inside
or near the tumour region, BFM is ill-suited for
delineation purposes. Logan VT maps show an
expected systemic underestimation mainly caused by
noise, as previously reported for other tracers.20 SA
does not show patches, but in terms of noise and accur-
acy of VT, it is inferior to the Logan maps in this study.
Therefore, Logan is the most precise method for mea-
suring VT at the voxel level. This conclusion also holds
if shorter (60min) dynamic scans are used.
The basis function implementations RPM and
SRTM2 showed patchiness similar to BFM. Possibly,
the patches arise from fit instability due to low tracer
uptake or from the violated assumption of single tissue
compartment models in both target and reference
regions. SRTM2 is less affected than RPM, which indi-
cates that the effect in RPM is partly caused by an
unstable k
0































































Figure 3. Filled circles represent the full 90 min dataset, filled
triangles the first 60 min, open circles the time interval of 60–
90 min, open triangles 40–60 min, open squares 20–40 min. (a)
Accuracy; bars represent mean and standard deviation. Please
note that the data points are from three regions inside the
tumour for each subject, thus data can be correlated. MRTM2 and
MRTM4 were excluded from this figure. (b) Noise estimated in
the DVR or BPNDþ1 maps; bars represent mean. RPM
60,
MRTM60O , MRTM, MRTM2, MRTM
60
3 and MRTM4 were excluded






































Figure 2. Circles represent the full 90 min dataset, triangles the
first 60 min. (a) Accuracy; bars represent mean and standard
deviation. Please note that the data points are from three regions
inside the tumour for each subject, thus data can be correlated.
(b) Noise estimated in VT maps; bars represent mean.
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values showed that for most voxels RPM chooses either
the upper or the lower limit, thus k
0
2 compensation is
needed to ensure good fits. When k
0
2 is fixed to a global
brain estimate in SRTM2, most patches disappear,
although some patches persist in areas with relatively
low rate constants. Again, these patches can be near or
in the tumour region. Therefore, the use of both RPM
and SRTM2 for delineation is questionable while they
perform well for assessing tracer uptake within (regions
of) the tumour.
The main purpose of MRTM is not the parametric
map itself, but providing a reliable k
0
2 estimate. The noise
in the MRTM maps was expected: as described in the
original paper the variability of the method increases
compared toMRTMO, but a better accuracy is achieved,
which is in line with the results here. Although a better
accuracy for DVR is achieved, the k
0
2 estimation is
unstable, causing large differences in the MRTM2 and
MRTM4 maps. Ichise et al. recommend to use regional
TACs where k
0
2 6¼k2 for MRTM’s k
0
2 estimation because
the method is not only sensitive to noise, but also
becomes unstable when the clearance rates become iden-
tical.21 We fixed k
0
2 for both MRTM2 and MRTM4
using a threshold on MRTM BPND>0—which has
worked well in the past17,22—but, given the sensitivity
to noise, it might be better to use region based signal(s)
for the k
0
2 estimation. The data show, however, that
clearance rates using a single tissue compartment
model can be very similar in both tumour and reference
region, especially in the lower grade diffuse gliomas.
Thus, finding a suitable reference region is problematic.
Although some optimization is possible, use of MRTM2
or MRTM4 is not promising for FET in glioma.
RLogan plots showed maps with the lowest noise
levels, but also with relatively low accuracy. MRTMO
showed better accuracy, and only a small increase in
noise. MRTM3 is comparable to MRTMO. SUVr
60–90
shows the best accuracy among the remaining methods
and is not much poorer in terms of noise. When only
60min data are available, SUVr40–60 is the best method
in terms of noise and only RPM60 and SRTM602 show
better accuracy. If 60min data are used, all MRTM
variations show more noise than the other methods.
SUVr is the easiest method to implement and it is
used in most studies since it is the currently recom-
mended method, although with an earlier tracer
uptake interval. The present results indicate, however,
that a later interval shows better agreement with DVR
derived using a two-tissue compartment model with
blood volume fraction. SUVr also showed less noise
at later intervals. From visual inspection of the
images, it is clear that the contrast between grey and
white matter also decreases. Although we have tried to
minimize partial volume effects by using a relatively
high cut-off value for the grey matter mask, the
higher contrast for earlier intervals might (partly)
explain the higher image noise estimates. Although
some methods show better results in terms of accuracy
or image noise, the SUVr maps show relatively good
results in both.
Inherent to SUVr images at later intervals is a
decreased tumour-to-normal ratio in high-grade gli-
omas; these tumours typically show decreasing activity
concentrations after an early peak, while the activity
concentration in the reference region is constant after
30min, approximately. This decreasing contrast
over time can make it harder to see and delineate
the tumour. In case of threshold-based delineation,
the decrease can pose a problem when the ratio
approaches noise levels in the image. An example of
this is found in Figure 1, where the extent of the
tumour is increasingly difficult to determine in the
later SUVr images compared to the SUVr20–40 image.
Although SUVr images at a later interval provided
better quantitative performance, their application will
prove problematic in some glioblastoma patients.
Future research should investigate whether changing
the time interval of SUVr images shows improvement
in clinical applications, such as improved sensitivity or
specificity in distinguishing between tumour and
normal tissue, and whether or not this outweighs the
problem of (too) low contrast in some patients.
Conclusion
In this study, we evaluated the performance of several
parametric methods for the analysis of dynamic brain
18F-FET PET studies. It was found that the optimal
method depends on the intended application. If a
region-based approach is used, BFM and RPM are rec-
ommended for most accurate estimation of VT and
DVR, respectively, despite patchy artefacts in the
images. If quantitative maps are required for accurate
estimates on voxel level, e.g. for assessing the location
of tumour boundaries or assessing tracer uptake distri-
bution, Logan graphical analysis and SUVr60–90
(tumour-to-normal maps at interval 60–90min) are
the most suitable methods for deriving VT and DVR,
respectively. For tumour-to-normal maps, longer or, in
case of static imaging, later scans provided better quan-
titative performance. Assessment of the clinical rele-
vance of these findings is needed. Because of the good
performance of SUVr, future studies could focus on the
clinical evaluation of SUVr, obtained at several tracer
uptake intervals.
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